semaglutide cardiovascular outcomes news Insights into research: Mechanisms, trials, and frontiers Lower risk of cardiovascular events

Watch-outs to know : Some scientists are concerned with Epitalon because the peptide interacts with telomeres

doi: 10.1016/j.bbadis.2021.166126 10 ReynoldsJCLaiRWWoodheadJSTJolyJHMitchellCJCameron-SmithDet al

It is characterized by the decreased flow of bile from the liver

No severe hypoglycemia nor DKA were reported

44 Due to these promising results, as well as its established cardiovascular safety, 42,45 investigational interest around this agent is intense, with multiple randomized trials exploring its effects on liver fibrosis and steatosis of diabetic and nondiabetic patients, when administered alone, in combination or in comparison with other agents, such as empagliflozin (on diabetics-NCT04639414), efinopegdutide (on diabetics and non-diabetics-NCT04944992), cilofexor and firsocostat (on diabetics and non-diabetics-NCT04971785)

doi:10.1007/BF02857783